Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lisa Carey
aTyr Pharma, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
91 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Atyr Investigative Site
Salvador, Estado de Bahia, Brazil
- Atyr Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
- Atyr Investigative Site
São Bernardo do Campo, Brazil
- Atyr Investigative Site
São Paulo, Brazil
- Atyr Investigative Site
São Paulo, Brazil
- Atyr Investigative Site
Bobigny, France
- Atyr Investigative Site
La Tronche, France
- Atyr Investigative Site
Montpellier, France
- Atyr Investigative Site
Paris, France
- Atyr Investigative Site
Toulouse, France
- Atyr Investigative Site
Essen, Germany
- Atyr Investigative Site
Freiburg im Breisgau, Germany
- Atyr Investigative Site
Hanover, Germany
- Atyr Investigative Site
Heidelberg, Germany
- Atyr Investigative Site
Catania, Italy
- Atyr Investigative Site
Florence, Italy
- Atyr Investigative Site
Forlì, Italy
- Atyr Investigative Site
Milan, Italy
- Atyr Investigative Site
Naples, Italy
- Atyr Investigative Site
Padua, Italy
- Atyr Investigative Site
Rome, Italy
- Atyr Investigative Site
Siena, Italy
- Atyr Investigative Site
Trieste, Italy
- Kyorin Investigative Site
Aomori, Japan
- Kyorin Investigative Site
Fukuoka, Japan
- Kyorin Investigative Site
Fukushima, Japan
- Kyorin Investigative Site
Hokkaido, Japan
- Kyorin Investigative Site
Hokkaido, Japan
- Kyorin Investigative Site
Hyōgo, Japan
- Kyorin Investigative Site
Kanagawa, Japan
- Kyorin Investigative Site
Kanagawa, Japan
- Atyr Investigative Site
Kumamoto, Japan
- Kyorin Investigative Site
Miyagi, Japan
- Kyorin Investigative Site
Okayama, Japan
- Kyorin Investigative Site
Osaka, Japan
- Kyorin Investigative Site
Shimane, Japan
- Kyorin Investigative Site
Shizuoka, Japan
- Kyorin Investigative Site
Tokyo, Japan
- Kyorin Investigative Site
Tokyo, Japan
- Atyr Investigative Site
Nieuwegein, Netherlands
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Sept 2022
- Primary completion
- 25 Jun 2025
- Completion
- 14 Jul 2025
- Last update posted
- 4 Jun 2026
- Registered enrollment
- 268
- Registry id
- NCT05415137
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.